法国泌尿外科协会癌症委员会前列腺癌推荐:2025年更新要点汇总
法国泌尿外科协会癌症委员会(CCAFU)对2024年7月至2025年9月文献进行系统综述,汇总前列腺癌诊疗推荐更新。双参数MRI在高质量成像和放射学专业能力前提下可替代多参数MRI引导活检决策;经会阴活检技术可行时推荐采用;HIFI试验标准的中危患者可选全腺体HIFU。
要点
- 双参数MRI可替代多参数MRI引导活检决策,前提是高质量成像和放射学专业能力。
- 经会阴活检技术可行时为推荐入路。
- 符合HIFI试验标准的中危前列腺癌患者,全腺体HIFU是一种治疗选择。
核心结论
- 本2025年更新汇总旨在帮助医生掌握前列腺癌管理的最新进展并改善患者管理。
研究设计与样本
- CCAFU对2024年7月至2025年9月文献进行系统综述,评估新发表参考文献及其证据级别,形成2025年推荐更新汇总。
诊断标准与关键数值
- 双参数MRI可替代多参数MRI引导活检决策,前提是实现高质量成像和放射学专业能力。
- 经会阴活检技术可行时为推荐入路。
- 符合HIFI试验标准的中危前列腺癌患者,全腺体HIFU是一种治疗选择。
- 寡转移激素敏感性前列腺癌(mHSPC)非症状驱动转移灶导向治疗时,应给予至少6个月雄激素剥夺治疗(ADT)。
- 按EMBARK标准治疗的高危生化复发(BCR)患者,可考虑恩扎卢胺单药系统治疗。
临床应用与阅片要点
- 双参数MRI替代多参数MRI需以保证高质量成像和放射学专业能力为前提。
- 经会阴活检在技术可行时为推荐入路。
- 全腺体HIFU仅适用于符合HIFI试验标准的中危前列腺癌患者。
- mHSPC寡转移非症状驱动转移灶导向治疗时,应给予至少6个月ADT。
- HRR基因改变者,尼拉帕利联合阿比特龙可作为mHSPC一线方案考虑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE OF THIS DOCUMENT: The Oncology Committee of the French Urology Association (CCAFU) is proposing a 2025 summary of recommendations' changes for the management of prostate cancer (PCa).
METHODS: A systematic review of the literature from July 2024 to September 2025 was conducted by the CCAFU on the evolutions of diagnostic and therapeutic management of PCa evaluating the newly published references with their level of evidence.
RESULTS: Biparametric MRI is an alternative to multiparametric MRI imaging to guide biopsy decision making provided that a high-quality imaging and radiology expertise is achieved. Transperineal biopsy is the recommended approach when technically feasible. Whole-gland HIFU in patients fulfilling the HIFI trial criteria is a treatment option for intermediate-risk PCa patients. In case of metastasis-directed therapy outside the context of symptoms for oligometastatic hormone-sensitive PCa (mHSPC) disease, at least 6 months of androgen deprivation therapy (ADT) should be given. In patients with high-risk BCR treated according to the EMBARK criteria, systemic treatment with monotherapy enzalutamide may be considered. The ARPI used in addition to ADT alone can be: abiraterone, apalutamide, darolutamide, enzalutamide. In the case of HRR alterations, the combination of niraparib and abiraterone may be proposed as first-line mHSPC. In the case of a positive radiolabelled PSMA ligand PET/CT scan in a patient progressing after at least one ARPI, internal radiotherapy using [177 Lu]LuPSMA-617 may be proposed. In patients with no or mildly symptomatic bone metastatic castration-resistant PCa without visceral metastases, the combination of enzalutamide+6 cycles of radium-223 may be proposed.
CONCLUSION: This 2025 summary of changes of French recommendations on PCa should help physicians to stay up-to-date with recent evolutions and aim to improve the management of PCa patients.
引用
- Ploussard G, Baboudjian M, Barret E, et al. French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes. Fr J Urol. 2025. PMID: 41109641. doi:10.1016/j.fjurol.2025.103010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。